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TACKLING CONFLICTS OF INTEREST
BMJ tackles FDA’s mote in eye while ignoring own
beam
Stephen Senn professor of statistics
School of Mathematics and Statistics, University of Glasgow, Glasgow G12 8QW, UK
Godlee implies that the US Food and Drug Administration
(FDA) should be blamed for reversing its decision when it
realises it has made a mistake.1 Only two months ago an FDA
panel voted to withdraw the breast cancer drug bevacizumab,
which had been given “accelerated approval” in 2008.2 Fast
track approval: is that foreign to the medical press? Well, ’pon
my soul, what did I find here http://resources.bmj.com/bmj/
authors/fast-track-publication? Publishing faulty and mistaken
articles: is that something that the BMJ never does? Leaving a
job to take up a commercial post: is that something that only
regulators do, or journal editors also? Perhaps the editor of the
BMJ might like to engage in a little local historical reflection.
So what are the real differences between the FDA and theBMJ?
I can think of at least two.
Firstly, the agency, unlike the journal, requires you to submit
your data files and your computer code with your application
so that the agency statisticians can spend weeks and months
checking your claims.
Secondly, the FDA does, indeed, reverse its decisions. On the
other hand, I seem to recall a particular editor admitting, “half
of what we publish is wrong; the problem is we don’t know
which half,” to which might be added, “but when we do know
it’s wrong we certainly don’t withdraw it.”
Compared with what the FDA does to ensure quality, the BMJ
is not even at square one. Instead of a policy of “original data
if you think it will help our reviewers or if we specifically
request it,” why doesn’t the journal say, “no data and computer
code, no BMJ article.” Instead of criticising the FDA, the BMJ
would do well to learn from it.
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